Are you a professional? Activate your profile

Are you already registered? Access Forgot your password?

Financial advisors
Calculation tools
- Calculates the risk and return of a securities portfolio
- Calculate your supplementary pension
News from the UK Stock Exchange

Funds / ETFs / Stock Ranking
Learn about finance
- Financial glossary
- Learning to invest
  The most important concepts of finance
Study Office
- Asset allocation
- Finance app ranking
About us

Hillevax Inc. - news published 123 - readings 1.390

BACK

Hillevax Inc.

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress (Form 8-K)

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives BOST ...

28.03.2025

Hillevax Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis together with our consolidated financial statements and related notes included in "Item 8. Financial Statements and Supplementary Data" in this Annual Report on Form 10-K. The following discussion contains forward-looking stateme ...

28.03.2025

Hillevax Inc.

Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. UNITED STATES SECURITIES AND EXCHANGE COMMISSIO ...

12.02.2025

Hillevax Inc.

Statement of Changes in Beneficial Ownership (Form 4)

12.02.2025

Hillevax Inc.

Management Change/Compensation Form 8 K

Item 2.05 Costs Associated with Exit or Disposal Activities. On December 4, 2024, HilleVax, Inc. (the "Company") commenced a workforce reduction of 28 employees, constituting approximately 70% of the Company's workforce, to reduce its operating expenses. The Company's remaining management and employees will continue to explore and evaluate the development of its noro ...

05.12.2024

Hillevax Inc.

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

The text version of this document is not available. You can access the original document here . Attachments Original document Permalink Disclaimer Hillevax Inc. published this content on November 07, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 07, 2024 at 13:52:52.563 .

07.11.2024

Hillevax Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission ...

07.11.2024

Hillevax Inc.

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress Form 8 K

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress $189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as business development related activities and other strategic alternatives ...

07.11.2024

Hillevax Inc.

Reorganization Form 8 K

Item 2.05 Costs Associated with Exit or Disposal Activities. On October 15, 2024, HilleVax, Inc. (the "Company") completed a workforce reduction of approximately 15 employees, constituting approximately 25% of the Company's workforce. The Company is taking this action to reduce its operating expenses while the Company explores the potential for continued development ...

16.10.2024

Hillevax Inc.

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Form 8 K

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is exploring the potential for continued development of its HIL-214 and HIL-216 norovirus vaccine candidates in adults BOSTON, August 8, 2024 - HilleVax, Inc. (Nasdaq: HLVX), a clinical- ...

09.08.2024

Hillevax Inc.

Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)

10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File ...

09.08.2024

Hillevax Inc.

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer Hillevax Inc. published this content on 08 August 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 08 August 2024 23:46:33 UTC .

08.08.2024

Hillevax Inc.

HilleVax Announces Reduction in Force

The text version of this document is not available. You can access the original document here . Attachments Original Link Permalink Disclaimer Hillevax Inc. published this content on 31 July 2024 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 31 July 2024 20:42:59 UTC .

31.07.2024

Hillevax Inc.

Costs Associated with Exit/Disposal Form 8 K

Item 2.05 Costs Associated with Exit or Disposal Activities. On July 31, 2024, HilleVax, Inc. (the "Company") announced a workforce reduction of approximately 41 employees, constituting approximately 40% of the Company's workforce. The Company is taking this action to reduce its operating expenses while maintaining core capabilities as the Company explores the potent ...

31.07.2024

Hillevax Inc.

Termination of Material Agreement Form 8 K

Item 1.02 Termination of a Material Definitive Agreement. On July 19, 2024, HilleVax, Inc. (the "Company") repaid in full the entire $26.2 million of outstanding principal and interest under its Loan and Security Agreement, as amended to date (the "Loan Agreement"), with Hercules Capital, Inc., as administrative and collateral agent, and the lenders from ti ...

23.07.2024

Hillevax Inc. - news published 123 - readings 1.390

Hillevax Inc.

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress (Form 8-K)

Hillevax Inc.

Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)

Hillevax Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Hillevax Inc.

Statement of Changes in Beneficial Ownership (Form 4)

Hillevax Inc.

Management Change/Compensation Form 8 K

Hillevax Inc.

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Hillevax Inc.

Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)

Hillevax Inc.

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress Form 8 K

Hillevax Inc.

Reorganization Form 8 K

Hillevax Inc.

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress Form 8 K

Hillevax Inc.

Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)

Hillevax Inc.

HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Hillevax Inc.

HilleVax Announces Reduction in Force

Hillevax Inc.

Costs Associated with Exit/Disposal Form 8 K

Hillevax Inc.

Termination of Material Agreement Form 8 K

You have reached the maximum number of requests. You can no longer send.

Become Member

€2,99per month

Become Member

€2,99per month

You have reached the maximum
number of requests.
You can no longer send.

Become
Member

Become
Member